Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Aimery de Gramont Clear advanced filters

  • A retrospective study of Medicare patients over 65 years of age with stage II colon cancer, showed that adjuvant chemotherapy did not improve overall survival, even in patients with poor prognostic factors. But, does this mean that these patients should not be offered this treatment option?boxed-text

    • Christophe Tournigand
    • Aimery de Gramont
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 8, P: 574-576

  • Biomarkers that predict a patient's responsiveness to anticancer therapies are of increasing importance during drug development and in clinical trials, as well as in the clinic. In this Review, the major challenges to biomarker development and standardization are discussed, and the considerations for validation of the pre-analytical, analytical and post-analytical protocols involved in biomarker assays are highlighted.

    • Armand de Gramont
    • Sarah Watson
    • Stanley R. Hamilton
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 12, P: 197-212

  • The validation of predictive and prognostic biomarkers and surrogate end points requires robust statistical analysis of data gathered from multiple, large, independent studies. In this Review, Marc Buyse and coauthors discuss this validation process and the nature of biomarkers and surrogate end points. Furthermore, they consider strategies for the pragmatic evaluation of biomarkers and surrogate end points in the absence of statistical validation.

    • Marc Buyse
    • Daniel J. Sargent
    • Aimery de Gramont
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 7, P: 309-317

  • Following the development of the first mTOR inhibitor that successfully improves therapeutic survival in cancer, Raymond and colleagues look at how novel biomarker identification and the use of multitargeted and multimodality therapies could advance the next generation of these drugs.

    • Sandrine Faivre
    • Guido Kroemer
    • Eric Raymond
    Reviews
    Nature Reviews Drug Discovery
    Volume: 5, P: 671-688